CoChat

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Open access
Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha · 2013 · Oncotarget
Cited by 115

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Aurélie Poli 1,2,* , Jian Wang 1,* , Olivia Domingues 2 , Jesús Planagumà 1 , Tao Yan 1,6 , Cecilie Brekke Rygh 1 , Kai Ove Skaftnesmo 1 , Frits Thorsen 1 , Emmet McCormack 3 , François Hentges 2 , Paal Henning Pedersen 4 , Jacques Zimmer 2 , Per Øyvind Enger 1,4 , and Martha Chekenya 1,5 1 Translational Cancer Research, Department of Biomedicine, University of Bergen, Norway 2 Laboratoire d’Immunogénétique-Allergologie, CRP-Santé, Luxembourg 3 Department of Medicine, Haukeland University Hospital, Bergen, Norway 4 Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway 5 Department of Clinical Dentistry, University of Bergen, Norway 6 Department of Neurosurgery, Qilu Hospital, Shandong University, P.R. China * These authors contributed equally Correspondence: Martha Chekenya, email: Keywords : Microglia, NK cells, glioblastoma, immunotherapy, NG2/CSPG4 Received : August 16, 2013 Accepted : September 7, 2013 Published : September 9, 2013 Abstract Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease. Although several immunotherapies are under development for the treatment of GBM patients, the use of natural killer (NK) cells is still marginal despite this being a promising approach to treat cancer. In regard of our knowledge on the role of NG2/ CSPG4 in promoting GBM aggressiveness we investigated the potential of an innovative immunotherapeutic strategy combining mAb9.2.27 against NG2/ CSPG4 and NK cells in preclinical animal models of GBM. Multiple immune escape mechanisms maintain the tumor microenvironment in an anti-inflammatory state to promote tumor growth, however, the distinct roles of resident microglia versus recruited macrophages is not elucidated. We hypothesized that exploiting the cytokine release capabilities of activated (NK) cells to reverse the anti-inflammatory axis combined with mAb9.2.27 targeting the NG2/ CSPG4 may favor tumor destruction by editing pro-GBM immune responses. Combination treatment with NK+mAb9.2.27 diminished tumor growth that was associated with reduced tumor proliferation, increased cellular apoptosis and prolonged survival compared to vehicle and monotherapy controls. The therapeutic efficacy was mediated by recruitment of CCR2 low macrophages into the tumor microenvironment, increased ED1 and MHC class II expression on microglia that might render them competent for GBM antigen presentation, as well as elevated IFN-γ and TNF-α levels in the cerebrospinal fluid compared to controls. Depletion of systemic macrophages by liposome-encapsulated clodronate decreased the CCR2 low macrophages recruited to the brain and abolished the beneficial outcomes. Moreover, mAb9.2.27 reversed tumor-promoting effects of patient-derived tumor-associated macrophage/microglia(TAM) ex vivo .Taken together, these findings indicate thatNK+mAb9.2.27 treatment may be an amenable therapeutic strategy to treat NG2/ CSPG4 expressing GBMs. We provide a novel conceptual approach of combination immunotherapy for glioblastoma. The results traverse beyond the elucidation of NG2/ CSPG4 as a therapeutic target, but demonstrate a proof of concept that this antibody may hold potential for the treatment of GBM by activation of tumor infiltrated microglia/macrophages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1291

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 115

Metadata

Authors
Poli, A., Wang, J., Domingues, O., Planagumà, J., Yan, T., Rygh, C. B., Skaftnesmo, K. O., Thorsen, F., McCormack, E., Hentges, F., Pedersen, P. H., Zimmer, J., Enger, P. Ø., & Chekenya, M.
Venue
Oncotarget
Published
2013-09-09
Volume
4
Issue
9
Pages
1527-1546
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1551006141
Cited by
115
References
8
FWCI
4.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.